DanGer Shock update: Impella CP heart pump linked to long-term survival benefit

The key figure from NEJM publication confirms the survival benefit of Impella CP increases year-over-year. Source: Møller J, et al. Long Term Outcomes of the DanGer Shock Trial. N Engl J Med 2025.

The key figure from NEJM publication confirms the survival benefit of Impella CP increases year-over-year. Source: Møller J, et al. Long Term Outcomes of the DanGer Shock Trial. N Engl J Med 2025.

When patients present with STEMI-related cardiogenic shock, treatment with the Impella CP appears to make a positive impact that lasts for at least a decade.

Q&A: Cardiologist explores CMS proposal to cover cardiac ablations performed in ambulatory surgical centers

Newsweek ranked the 50 best heart hospitals in the world

CMS has proposed a policy shift that would allow cardiac ablation procedures to be performed in ambulatory surgical centers. Arash Aryana, MD, PhD, a veteran cardiac electrophysiologist, explained why he is "extremely encouraged" by this proposal, highlighting several potential benefits.